Online inquiry

IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4129MR)

This product GTTS-WQ4129MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ICAM1 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000201.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3383
UniProt ID P05362
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ4129MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11470MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ1700MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ7774MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GS-5745
GTTS-WQ10592MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3127804
GTTS-WQ10577MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY-3127804
GTTS-WQ5188MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CAT-354
GTTS-WQ13787MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-10933
GTTS-WQ3221MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ARGX-110
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW